항체-약물 접합체(ADC) 시장 기회, 성장요인, 업계 동향 분석 및 예측(2025-2034년)

The Global Antibody Drug Conjugates Market was valued at USD 12.9 billion in 2024 and is estimated to grow at a CAGR of 10.3% to reach USD 34.1 billion by 2034.

Market expansion is driven by the rising prevalence of various cancers, including blood, breast, urothelial, and bladder cancers worldwide. The increasing cancer burden is creating urgent demand for more precise and effective therapies, making ADCs a critical component of modern oncology treatment. Antibody drug conjugates combine targeted therapy with chemotherapy, delivering potent cytotoxic agents directly to cancer cells while sparing healthy tissues. These therapies use monoclonal antibodies linked to highly potent drugs through chemical linkers, ensuring that the cytotoxic agent binds specifically to antigens on tumor cells, which enhances treatment efficacy and reduces collateral damage. As cancer rates rise, particularly in aging populations and emerging markets, the adoption of ADCs is expected to accelerate.

The Enhertu segment held a 29.1% share, valued at USD 3.8 billion in 2024. Its broad therapeutic application across multiple cancer types, including HER2-positive and HER2-low tumors, has expanded the patient pool, providing a competitive advantage over other ADCs. Clinical trial results demonstrate high response rates and improved overall survival, contributing to its strong adoption among oncologists.

The cleavable linker segment generated USD 10.6 billion in 2024 and is projected to grow at a CAGR of 10.2%. Cleavable linkers release the cytotoxic drug specifically within the tumor microenvironment, triggered by enzymes, pH changes, or redox conditions. This targeted release maximizes tumor cell destruction while minimizing damage to healthy tissues, giving cleavable linker ADCs a clear clinical advantage over non-cleavable variants.

North America Antibody Drug Conjugates Market held a 42.1% share in 2024. The region benefits from a well-established healthcare infrastructure, a large cancer patient population, and the presence of leading players offering advanced oncology treatments. Strong R&D investments, favorable regulatory frameworks, and early adoption of innovative therapies support the rapid introduction and uptake of new ADC products.

Key players operating in the Global Antibody Drug Conjugates Market include AbbVie, Astellas Pharma, ADC Therapeutics, AstraZeneca, Daiichi Sankyo, Gilead, GSK, ImmunoGen, Pfizer, and Roche. Companies in the Antibody Drug Conjugates Market are strengthening their foothold by investing heavily in research and development to discover new ADC candidates targeting multiple cancer types and improving clinical efficacy. Strategic collaborations with biotech firms and academic institutions help accelerate innovation and streamline regulatory approvals. Firms are also expanding manufacturing capacity to ensure timely global supply and entering emerging markets to capture new patient populations. Leveraging targeted marketing campaigns, clinical trial data, and educational programs for oncologists enhances product adoption.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 Technology trends
  • 2.2.4 Application trends
  • 2.2.5 Target type trends
  • 2.2.6 End Use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer
    • 3.2.1.2 Growing demand for antibody-based cancer therapies
    • 3.2.1.3 Increasing advancements in antibody technology
    • 3.2.1.4 Expanding approval of ADCs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development and manufacturing costs
    • 3.2.2.2 Safety and toxicity concerns associated with ADCs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion into solid tumors
    • 3.2.3.2 Adoption of next-generation ADC technologies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pipeline analysis
• 3.7 Global cancer statistics
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Enhertu
• 5.3 Kadcyla
• 5.4 Adcetris
• 5.5 Padcev
• 5.6 Trodelvy
• 5.7 Polivy
• 5.8 Other product types

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Cleavable linker
• 6.3 Non-cleavable linker

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Breast cancer
• 7.3 Blood cancer
  • 7.3.1 Lymphoma
  • 7.3.2 Leukemia
  • 7.3.3 Multiple myeloma
• 7.4 Urothelial cancer and bladder cancer
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Target Type, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 HER2
• 8.3 CD30
• 8.4 CD22
• 8.5 Other target types

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Oncology centers
• 9.4 Other End Use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AbbVie
• 11.2 ADC Therapeutics
• 11.3 Astellas Pharma
• 11.4 AstraZeneca
• 11.5 Daiichi Sankyo
• 11.6 Gilead
• 11.7 GSK
• 11.8 ImmunoGen
• 11.9 Pfizer
• 11.10 Roche